Compare Citius Pharmaceuticals Inc (CTXR) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs JPMorgan Chase & Co — how do they compare? Citius Pharmaceuticals Inc trades at $0.72 (market cap $20.01M), while JPMorgan Chase & Co trades at $364.91 (market cap $962.37B). The key difference: JPMorgan Chase & Co is far larger — about 48094.5× Citius Pharmaceuticals Inc's market cap, and JPMorgan Chase & Co pays a 1.66% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | JPM | |
|---|---|---|
Market Cap | $20.01M | $962.37B |
Sector | Health | Financials |
52-Week High | $1.82 | $362.04 |
52-Week Low | $0.48 | $282.84 |
Enterprise Value | $16.23M | — |
Volume | — | 10,479,943 |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
JPMorgan Chase & Co. (JPM) trades at $365.11, up 1.48% in 24 hours, with a bullish technical signal and strong fundamentals including a 33.38% net income margin and 18.43% ROE. Recent earnings beat expectations in Q1 and Q2 2026, while analyst consensus is a Moderate Buy with a $374.18 price target. CEO Jamie Dimon's shareholder letter highlights economic risks, but institutional buying and resilient sector performance support optimism.
The outlook for JPM is positive, driven by earnings momentum and sector strength, though risks include geopolitical tensions and potential economic headwinds noted by management. Upside to the consensus target offers opportunity, but investors should weigh high RSI levels and macroeconomic cautions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
